J
Jennifer L. Hsu
Researcher at University of Texas MD Anderson Cancer Center
Publications - 95
Citations - 9553
Jennifer L. Hsu is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 36, co-authored 90 publications receiving 6077 citations. Previous affiliations of Jennifer L. Hsu include China Medical University (Taiwan) & China Medical University (PRC).
Papers
More filters
Journal ArticleDOI
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs
Chun Ju Chang,Chi-Hong Chao,Weiya Xia,Jer Yen Yang,Jer Yen Yang,Yan Xiong,Chia Wei Li,Wen Hsuan Yu,Sumaiyah K. Rehman,Jennifer L. Hsu,Heng Huan Lee,Mo Liu,Chun Te Chen,Dihua Yu,Mien Chie Hung +14 more
TL;DR: This study elucidates a role for p53 in regulating EMT–MET (mesenchymal–epithelial transition) and stemness or differentiation plasticity, and reveals a potential therapeutic implication to suppress EMT-associated cancer stem cells through activation of the p53–miR-200c pathway.
Journal ArticleDOI
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia Wei Li,Seung Oe Lim,Weiya Xia,Heng Huan Lee,Li Chuan Chan,Li Chuan Chan,Chu Wei Kuo,Kay-Hooi Khoo,Shih Shin Chang,Jong Ho Cha,Taewan Kim,Jennifer L. Hsu,Jennifer L. Hsu,Jennifer L. Hsu,Yun Wu,Jung Mao Hsu,Hirohito Yamaguchi,Qingqing Ding,Yan Wang,Jun Yao,Cheng Chung Lee,Hsing Ju Wu,Aysegul A. Sahin,James P. Allison,Dihua Yu,Gabriel N. Hortobagyi,Mien Chie Hung +26 more
TL;DR: The results link ubiquitination and glycosylation pathways to the stringent regulation of PD-L1, which could lead to potential therapeutic strategies to enhance cancer immune therapy efficacy.
Journal ArticleDOI
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Shiping Jiao,Shiping Jiao,Weiya Xia,Hirohito Yamaguchi,Yongkun Wei,Mei-Kuang Chen,Mei-Kuang Chen,Jung Mao Hsu,Jennifer L. Hsu,Jennifer L. Hsu,Jennifer L. Hsu,Wen Hsuan Yu,Wen Hsuan Yu,Yi Du,Heng Huan Lee,Chia Wei Li,Chao Kai Chou,Seung Oe Lim,Shih Shin Chang,Jennifer K. Litton,Banu Arun,Gabriel N. Hortobagyi,Mien Chie Hung +22 more
TL;DR: A cross-talk between PARPi and tumor-associated immunosuppression is demonstrated and evidence is provided to support the combination of PAR Pi and PD-L1 or PD-1 immune checkpoint blockade as a potential therapeutic approach to treat breast cancer.
Journal ArticleDOI
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung Oe Lim,Chia Wei Li,Weiya Xia,Jong Ho Cha,Li Chuan Chan,Yun Wu,Shih Shin Chang,Shih Shin Chang,Wan Chi Lin,Jung Mao Hsu,Yi Hsin Hsu,Taewan Kim,Wei Chao Chang,Jennifer L. Hsu,Hirohito Yamaguchi,Qingqing Ding,Yan Wang,Yi Yang,Chung-Hsuan Chen,Aysegul A. Sahin,Dihua Yu,Dihua Yu,Gabriel N. Hortobagyi,Mien Chie Hung +23 more
TL;DR: It is demonstrated that COP9 signalosome 5 (CSN5), induced by NF-κB p65, is required for TNF-α-mediated PD-L1 stabilization in cancer cells, and inhibition of CSN5 by curcumin diminished cancer cell PD- L1 expression and sensitized cancer cells to anti-CTLA4 therapy.
Journal ArticleDOI
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Jong Ho Cha,Wen Hao Yang,Weiya Xia,Yongkun Wei,Li Chuan Chan,Seung Oe Lim,Chia Wei Li,Taewan Kim,Shih Shin Chang,Heng Huan Lee,Jennifer L. Hsu,Hung Ling Wang,Chu Wei Kuo,Wei Chao Chang,Sirwan Hadad,Colin A. Purdie,Aaron McCoy,Shirong Cai,Yizheng Tu,Jennifer K. Litton,Elizabeth A. Mittendorf,Stacy L. Moulder,William Fraser Symmans,Alastair M. Thompson,Helen Piwnica-Worms,Chung-Hsuan Chen,Kay-Hooi Khoo,Mien Chie Hung +27 more
TL;DR: It is shown that metformin increases CTL activity by reducing the stability and membrane localization of programmed death ligand-1 (PD-L1), and it is discovered that AMP-activated protein kinase (AMPK) activated by met formin directly phosphorylates S195 of PD-L 1.